TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06345495: High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT06345495 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06345495 Rescue Dossier →